» Articles » PMID: 33037006

T and Genetic Variations Between Asian and Caucasian Polypoidal Choroidal Vasculopathy

Abstract

Purpose: To compare phenotypic and genetic variations in polypoidal choroidal vasculopathy (PCV) between Caucasian and Asian patients.

Methods: We analysed phenotypic and genotypic data from two sites, Association for Innovation and Biomedical Research on Light and Image, Portugal and Singapore National Eye Centre, Singapore. Baseline fundus photography, spectral domain-optical coherence tomography, indocyanine green and fluorescein angiography scans were analysed by respective reading centres using a standardised grading protocol. Single nucleotide polymorphisms across 8 PCV loci were compared between cases and controls selected from each population.

Results: One hundred and forty treatment-naïve PCV participants (35 Portuguese and 105 Singaporean) were included. The Portuguese cohort were older (72.33±8.44 vs 68.71±9.40 years, p=0.043) and were comprised of a lower proportion of males (43% vs 71%, p=0.005) compared with the Singaporean cohort. Differences in imaging features include higher prevalence of soft drusen (66% vs 30%, p=0.004), lower prevalence of subretinal haemorrhage (14% vs 67%, p<0.001), smaller polypoidal lesion (PL) area (0.09±0.09 vs 0.76±0.93 mm, p<0.001), lower ratio of PL to branching vascular network area (3% vs 38%, p<0.001) and lower central retinal thickness (346.48±93.74 vs 493.16±212.92 µm, p<0.001) in the Portuguese cohort. (OR 2.467; 95% CI 1.282 to 4.745, p=0.006) in the Portuguese population was significantly associated with PCV and (OR 1.719; 95% CI 1.139 to 2.596, p=0.010) in the Singaporean population, respectively.

Conclusion: Among Asian and Caucasian patients with PCV, there are significant differences in the expression of phenotype. We also identified different polymorphisms associated with PCV in the two populations.

Citing Articles

Imaging characterization of the fellow eye in patients with unilateral polypoidal choroidal vasculopathy.

Pereira P, Simao J, Silva C, Farinha C, Murta J, Silva R Int Ophthalmol. 2024; 44(1):122.

PMID: 38427135 DOI: 10.1007/s10792-024-03048-2.


Macular neovascularization and polypoidal choroidal vasculopathy: phenotypic variations, pathogenic mechanisms and implications in management.

Cheung C Eye (Lond). 2023; 38(4):659-667.

PMID: 37803144 PMC: 10920817. DOI: 10.1038/s41433-023-02764-w.


Different Morphology of Branching Neovascular Network in Polypoidal Choroidal Vasculopathy: A Swept-Source Optical Coherence Tomography Angiography Study.

Chen L, Yuan M, Sun L, Chen Y J Clin Med. 2023; 12(3).

PMID: 36769390 PMC: 9918075. DOI: 10.3390/jcm12030742.


Current Trends in Clinical Characteristics, Diagnosis, and Treatment of Polypoidal Choroidal Vasculopathy: A Perspective from Vietnam.

Dat D, Hien N, Quan N, Tung M, Tam H, Hung B J Clin Med. 2022; 11(16).

PMID: 36012915 PMC: 9410352. DOI: 10.3390/jcm11164678.


Real-world cost-effectiveness of anti-VEGF monotherapy and combination therapy for the treatment of polypoidal choroidal vasculopathy.

Chay J, Fenner B, Finkelstein E, Teo K, Cheung C Eye (Lond). 2021; 36(12):2265-2270.

PMID: 34811522 PMC: 9674616. DOI: 10.1038/s41433-021-01856-9.